Fusion Antibodies plc

LSE:FAB.L

Sector

🏥 Health Care

Industries

🧬 Biotechnology

💊 Pharmaceuticals

🔍 Research & Consulting

Location

United Kingdom

Market Cap

USD 15.74 M

Share Price

USD 0.14

Avg Daily Volume

1,009,399

Change (1 day)

-2.19%

Change (1 year)

230.36%

Change (YTD)

54.09%

Fusion Antibodies plc Return on Assets (ROA) for the year ending March 31, 2019: -20.25%

Fusion Antibodies plc Return on Assets (ROA) is -20.25% for the year ending March 31, 2019, a 108.59% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Fusion Antibodies plc Return on Assets (ROA) for the year ending March 31, 2018 was -9.71%.

Competitors

Eli Lilly and Company

USD 635.22

LLY

+9.57 1.53%

AbbVie Inc.

USD 198.64

ABBV

+0.59 0.30%

Roche Holding AG

USD 317.50

RO.SW

-1.30 -0.41%

AstraZeneca PLC

USD 150.15

AZN.L

-2.01 -1.32%

Merck & Co., Inc.

USD 80.03

MRK

-0.66 -0.82%

Thermo Fisher Scientific Inc.

USD 462.39

TMO

+1.67 0.36%

Amgen Inc.

USD 285.09

AMGN

-3.14 -1.09%

Sanofi

USD 94.48

SAN.PA

+0.27 0.29%

Vertex Pharmaceuticals Incorporated

USD 374.46

VRTX

+7.92 2.16%

Chugai Pharmaceutical Co., Ltd.

USD 41.68

4519.T

+0.46 1.11%

Regeneron Pharmaceuticals, Inc.

USD 545.94

REGN

-17.06 -3.03%

MERCK Kommanditgesellschaft auf Aktien

USD 125.45

MRK.DE

-0.39 -0.31%

Samsung Biologics Co.,Ltd.

USD 741.26

207940.KS

+3.38 0.46%

Daiichi Sankyo Company, Limited

USD 24.22

4568.T

+0.20 0.82%

Ucb S.A.

USD 216.75

UCB.BR

+1.97 0.92%

View all

Key Data

Date	Return on Assets (ROA)	Revenue Per Share	Free Cash Flow Per Share	Dividend Per Share